Brokerages expect Omnicell, Inc. (NASDAQ:OMCL) to post earnings per share of $0.20 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Omnicell’s earnings. Omnicell posted earnings per share of $0.30 during the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The company is scheduled to report its next earnings report on Thursday, October 26th.

On average, analysts expect that Omnicell will report full-year earnings of $0.27 per share for the current financial year. For the next fiscal year, analysts anticipate that the business will report earnings of $1.23 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Omnicell.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the company earned $0.38 earnings per share.

Several equities research analysts recently issued reports on the company. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. CIBC upped their price target on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. TheStreet lowered Omnicell from a “b-” rating to a “c+” rating in a research report on Thursday, May 4th. Finally, Piper Jaffray Companies lowered Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price target on the stock. in a research report on Friday, April 21st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $49.00.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/11/1372277.html.

In related news, Chairman Randall A. Lipps sold 9,900 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $43.00, for a total transaction of $425,700.00. Following the completion of the transaction, the chairman now directly owns 208,982 shares in the company, valued at approximately $8,986,226. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP J Christopher Drew sold 11,375 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $51.16, for a total value of $581,945.00. Following the transaction, the vice president now owns 139,201 shares of the company’s stock, valued at $7,121,523.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 199,823 shares of company stock valued at $9,301,391. 3.77% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock worth $182,412,000 after buying an additional 4,484,128 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Omnicell by 580.1% in the first quarter. Eagle Asset Management Inc. now owns 793,649 shares of the company’s stock worth $32,261,000 after buying an additional 676,955 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Omnicell by 124.9% in the second quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock worth $28,481,000 after buying an additional 367,019 shares during the last quarter. Norges Bank bought a new position in shares of Omnicell during the fourth quarter worth approximately $10,913,000. Finally, Wells Fargo & Company MN increased its position in shares of Omnicell by 99.6% in the first quarter. Wells Fargo & Company MN now owns 561,295 shares of the company’s stock worth $22,817,000 after buying an additional 280,017 shares during the last quarter. Hedge funds and other institutional investors own 96.35% of the company’s stock.

Omnicell (NASDAQ OMCL) opened at 49.00 on Friday. Omnicell has a 12 month low of $30.35 and a 12 month high of $51.98. The stock’s market capitalization is $1.84 billion. The stock’s 50 day moving average is $45.19 and its 200-day moving average is $41.05.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.